Two interventions can share proposed pathways without one necessarily increasing the other's circulating signal. Direct measurement is needed to test that hypothesis. Primary study
What was reported
Researchers retrospectively analyzed paired serum samples from 38 participants in METTEN, nineteen per treatment arm. Women with HER2-positive breast cancer received neoadjuvant chemotherapy and trastuzumab with or without metformin. After 24 weeks, circulating MOTS-c did not change significantly, and changes did not significantly distinguish pathological complete-response groups. Primary report
Our appraisal: a parent randomized trial does not make every analysis primary
The treatment assignment came from a randomized study, but the peptide analysis was a later investigation of available samples. Its purpose, sample selection, and uncertainty need to be described separately from the parent trial's original outcomes.
A neutral biomarker result is informative about the proposed link. It does not establish that the underlying drugs share no biology or that every tissue response is absent. The measured outcome was circulating immunoreactivity under a particular sampling schedule.
Assay comparability is especially relevant when different reports give very different concentration ranges. Before comparing values across papers, the measured species and calibration need attention. A numerical result from one kit should not automatically be treated as interchangeable with another method.
The pathological-response analysis is also not a trial of administering MOTS-c. It asks whether changes in an endogenous measurement relate to an outcome during other treatment. A nonsignificant relationship should not become either a peptide cancer-treatment claim or proof that the biomarker can never be useful.
The defensible conclusion is a small, retrospective biomarker analysis with neutral reported comparisons. It challenges a simple assumption that adding metformin necessarily raises circulating MOTS-c in this clinical setting.
Frequently asked questions
Was MOTS-c the administered intervention?
No.
How many paired sample sets were analyzed?
Thirty-eight.
Was added metformin associated with a significant MOTS-c rise?
No.
Was the biomarker analysis part of the original design?
It was a retrospective analysis.
Did MOTS-c changes significantly distinguish pathological response?
Not in the reported analysis.
Are different assays automatically interchangeable?
No.
Is this evidence for treating cancer with MOTS-c?
No.